Table 1:
Patient Characteristics
| Demographics n = 36 | ||
| Median Age (range) | 55 years (27–72) | |
| Male | 20 (56%) | |
| Disease for Transplant | ||
| AML | 15 (44%) | |
| MDS/MPN | 12 (31%) | |
| Others | 9 (25%) | |
| Stem cell sources | ||
| Matched-Sibling | 7 (19%) | |
| Haploidentical Related | 5 (14%) | |
| Unrelated | 24 (67%) | |
| Conditioning regimens | ||
| Myeloblative | 35 (97%) | |
| Reduced Intensity | 1 (3%) | |
| GVHD Prophylaxis* | ||
| CNI/MTX | 23 (64%) | |
| CNI/MMF/PT CY | 7 (19%) | |
| Others | 6 (17%) | |
| GVHD Treatment | ||
| Median number of treatments | ||
| Prior to Ruxolitinib | 2 (0–5) | |
| With Ruxolitinib | 1.5 (0–5) | |
| Median time from steroid start to Rxolitiib | 16.5 (2–280) | |
| Starting dose of ruxolitinib | ||
| 5mg Daily | 1 (3%) | |
| 5mg BID | 26 (72%) | |
| 10 mg BID | 9 (25%) | |
| Ruxolitinib treatment Duration | ||
| Median Days (range) | 21.5 (1–560) | |
| ≥14 days of treatment | 67% | |
| Evaluable for Response (n = 24) | ||
| Complete Response | 6 (25%) | |
| Partial Response | 8 (33%) | |
| No Response | 10 (42%) | |
| Risk Factor | Responders | Non-responders |
|---|---|---|
| Skin-aGVHD | 7 (50%) | 2 (20%) |
| GI-aGVHD | 10 (71%) | 8 (80%) |
| Liver-aGVHD | 2 (15%) | 5 (50%) |
| > 1 organ | 5 (35%) | 6 (60%) |
| Low Albumin | 13 (93%) | 8 (80%) |
| Reason for discontinuation | ||
| Treatment failure | 15 (64%) | |
| Relapse of primary disease | 1 (3%) | |
| Cytopenias | 3 (14%) | |
| Issues obtaining ruxolitinib | 4 (17%) | |
| Complete Response | 1 (3%) | |
*
GVHD prophylaxis included calcineurin inhibitors (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF); post‐transplant cyclophosphamide (PT CY)